Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Background: With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute r...

Descripción completa

Detalles Bibliográficos

Publicado en:	Lancet Infectious Diseases Vol. 21; no. 2; pp. 181 - 193
Autores principales:	Zhang, Yanjun, Zeng, Gang, Pan, Hongxing, Li, Changgui, Hu, Yaling, Chu, Kai, Han, Weixiao, Chen, Zhen, Tang, Rong, Yin, Weidong, Chen, Xin, Hu, Yuansheng, Liu, Xiaoyong, Jiang, Congbing, Li, Jingxin, Yang, Minnan, Song, Yan, Wang, Xiangxi, Gao, Qiang, Zhu, Fengcai
Formato:	research Journal Article
Publicado:	Elsevier B.V. Feb2021
Acceso en línea:	Ver este registro en EBSCOhost